Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (PHAT) is a clinical-stage biopharmaceutical company advancing innovative treatments through its FDA-approved therapy vonoprazan. This page aggregates all essential updates related to PHAT's progress in gastrointestinal medicine, providing investors and medical professionals with a centralized news source.
Discover official announcements covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated selection emphasizes transparency, offering neutral reporting on financial results, research breakthroughs, and market expansion efforts without investment bias.
Key focus areas include vonoprazan's commercialization progress, new therapeutic applications under investigation, and analyses of PHAT's role in evolving acid suppression therapies. Content is maintained to reflect the company's position at the forefront of GI treatment innovation.
Bookmark this page for streamlined access to Phathom's verified announcements. Regular updates ensure stakeholders stay informed about developments shaping the company's trajectory in biopharmaceutical markets.
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in two upcoming investor conferences. The first is the 22nd Annual Needham Virtual Healthcare Conference, where a fireside chat is scheduled for April 18, 2023, at 8:45 a.m. EDT, with one-on-one meetings throughout the conference from April 17-20, 2023. The second event is the H.C. Wainwright BioConnect Investor Conference in New York City, featuring a fireside chat on May 2, 2023, at 2:30 p.m. EDT. Investors can access live webcasts and archived recordings of these chats via the company’s website for 90 days post-event. Phathom focuses on novel treatments for gastrointestinal diseases, with exclusive rights to vonoprazan, a potassium-competitive acid blocker.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced favorable feedback from the U.S. FDA that paves the way for a planned resubmission of its erosive esophagitis new drug application (NDA) within this quarter. The approval could facilitate a combined commercial launch of vonoprazan for erosive esophagitis and H. pylori indications in Q4 2023. Following extensive investigations into nitrosamine impurities, Phathom has mitigated the related issues and presented stability data to the FDA. The company remains optimistic about fulfilling all requirements for regulatory approvals by year-end.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported its 2022 financial results, revealing a net loss of $197.7 million, an increase from $143.9 million in 2021. In Q4 alone, losses reached $55 million, influenced by elevated R&D and administrative expenses. Major highlights included positive topline results from a Phase 3 trial for vonoprazan in treating non-erosive gastroesophageal reflux disease (GERD), alongside FDA approvals for related products. A meeting with the FDA is scheduled for March 2023 to discuss resubmission requirements for new drug applications, although the commercial launch is paused due to a nitrosamine impurity issue.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
